These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8562263)

  • 1. [The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
    Raiteri M; Arnaboldi L; Quarato P; Paoletti R; Fumagalli R; Corsini A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():35S-42S. PubMed ID: 8562263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
    Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
    Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct effects of statins on the vascular wall.
    Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
    J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct vascular effects of HMG-CoA reductase inhibitors.
    Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
    Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R
    Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
    Hughes AD
    J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation.
    Soma MR; Parolini C; Donetti E; Fumagalli R; Paoletti R
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S20-4. PubMed ID: 8907210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
    Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
    Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
    Yasunari K; Maeda K; Minami M; Yoshikawa J
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
    Soma MR; Donetti E; Parolini C; Mazzini G; Ferrari C; Fumagalli R; Paoletti R
    Arterioscler Thromb; 1993 Apr; 13(4):571-8. PubMed ID: 8466892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
    Ito T; Ikeda U; Shimpo M; Ohki R; Takahashi M; Yamamoto K; Shimada K
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):121-6. PubMed ID: 12090904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions.
    Robinson AJ; Kashanin D; O'Dowd F; Fitzgerald K; Williams V; Walsh GM
    Clin Exp Allergy; 2009 Dec; 39(12):1866-74. PubMed ID: 19689459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes.
    Corsini A; Raiteri M; Soma M; Fumagalli R; Paoletti R
    Pharmacol Res; 1991 Feb; 23(2):173-80. PubMed ID: 1905808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.